Prion Protein Fragment PrP-(106–126) Induces Apoptosis via Mitochondrial Disruption in Human Neuronal SH-SY5Y Cells

• Published in: The Journal of biological chemistry Vol. 276; no. 47; pp. 43516 - 43523
• Main Authors: O'Donovan, Conor N., Tobin, Deirdre, Cotter, Thomas G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 23-11-2001; American Society for Biochemistry and Molecular Biology
• Subjects: Apoptosis - physiology; Calcium - metabolism; Calpain - metabolism; Homeostasis - physiology; Humans; Mitochondria - metabolism; Mitochondria - pathology; Neurons - metabolism; Neurons - pathology; Oxidative Stress; Peptide Fragments - physiology; Prions - physiology; Tumor Cells, Cultured
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M103894200

The synthetic peptide PrP-(106–126) has previously been shown to be neurotoxic. Here, for the first time, we report that it induces apoptosis in the human neuroblastoma cell line SH-SY5Y. The earliest detectable apoptotic event in this system is the rapid depolarization of mitochondrial membranes, occurring immediately upon treatment of cells with PrP-(106–126). Subsequent to this, cytochrome c release and caspase activation were observed. Caspase inhibitors demonstrated that while the peptide activates caspases they are not an absolute requirement for apoptosis. Parallel to caspase activation, PrP-(106–126) was also observed to trigger a rise in intracellular calcium through release of mitochondrial calcium stores. This leads to the activation of calpains, another family of proteases. A calpain inhibitor demonstrated that while calpains are activated by the peptide they also are not an absolute requirement for apoptosis. Interestingly a combination of caspase and calpain inhibitors significantly inhibited apoptosis. This illustrates alternative pathways leading to apoptosis via caspases and calpains and that blocking both pathways is required to inhibit apoptosis. These results implicate the mitochondrion as a primary site of action of PrP-(106–126).